Simulations Plus, Inc. (Nasdaq: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery...
U.S. FDA Renews Annual DILIsym Software Licenses
FDA Maintains Access to Leading Liver Injury Software Program
Simulations Plus Reports Record Second Quarter FY2020 Revenue
Quarterly Revenues Up 22%; Board of Directors Announces Quarterly Dividend of $0.06 Per Share
Simulations Plus Partners with Large Pharmaceutical Company to Enhance High-Throughput PBPK Capabilities in ADMET Predictor®
Updated Functionality Seamlessly Integrates Mechanistic Modeling in Drug Discovery
Simulations Plus Sets Date for 2nd Quarter 2020 Earnings Release and Conference Call
Conference Call to be on Thursday, April 9, 2020, at 4:15 PM ET
Simulations Plus Acquires Lixoft, Expanding Modeling Software Offerings and Broadening Presence in Europe
Accretive acquisition adds Monolix Suite, a population PKPD modeling solution for pharmacometricians
Simulations Plus Sets Date for 2nd Quarter 2020 Earnings Release and Conference Call
Conference Call to be on Thursday, April 9, 2020, at 4:15 PM ET
Simulations Plus Offers Rapid Response COVID-19 Research Initiative
New StrategiesPlus™ program created for collaborative research acceleration
Sandra Suarez-Sharp Joins Simulations Plus to Lead Regulatory Strategies Team
Simulations Plus today announced the addition of Sandra Suarez-Sharp as Vice President, Regulatory Affairs to lead the new Regulatory Strategies team.
20-year FDA Master Reviewer will advise the planning of drug development programs with sponsor companies
DILIsym Services Partners with Large Pharmaceutical Company to Begin QSP Model Development for Heart Failure
QSP Modeling Project Targeted at Prevention of Heart Failure
Simulations Plus to Present at the 22nd Annual Needham Growth Conference
Simulations Plus to Present at the 22nd Annual Needham Growth Conference
Simulations Plus Reports Record First Quarter FY2020 Financial Results
First quarter net revenues of $9.4 million reflecting 24.8% year-over-year growth
Simulations Plus Sets Date for First Quarter Fiscal Year 2020 Earnings Release and Conference Call
Conference Call to be on Thursday, January 9, 2020, at 4:15 PM ET
Simulations Plus Partners with Bayer AG to Develop New Cheminformatics Capabilities in ADMET Predictor
New Structure and Tautomer Handling Routines Aim to Improve Data Integrity in Drug Discovery
Simulations Plus Partners with Large Pharmaceutical Company to Add New Capabilities to PKPlus
Funded customization project will enhance and simplify high-throughput processing of PK/TK datasets
Simulations Plus Partners with Large Pharmaceutical Company to Enhance the Mechanistic Oral Absorption (ACAT) Model in GastroPlus
Funded collaborative research effort adds new functionality to the top-rated simulation engine.
Simulations Plus Reports FY2019 and Fourth Quarter FY2019 Financial Results
Full-Year Revenue Increased 14.5% to $34 Million
Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2019 Earnings Release and Conference Call
Conference Call to be on Wednesday, November 13, 2019, at 4:15 PM ET
Simulations Plus to Support Development of Radiation Countermeasure via New QSP Platform (RADAsym) and Pharmacometrics Modeling
QSP and Pharmacometric Strategies Used to Aid Lifesaving Therapy for ARS
Simulations Plus Partners with Large Pharmaceutical Company to Develop the Virtual Bioequivalence Trial Simulator™ Module
Funded collaborative research effort strengthens the population simulation functionality in GastroPlus®